Qingfeng Chen
0000-0001-6437-1271
12 papers found
Refreshing results…
Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma
Potentiating Gilteritinib Efficacy Using Nanocomplexation with a Hyaluronic Acid–Epigallocatechin Gallate Conjugate
Emerging Preclinical Applications of Humanized Mouse Models in the Discovery and Validation of Novel Immunotherapeutics and Their Mechanisms of Action for Improved Cancer Treatment
Supplementary Data from IL12/18/21 Preactivation Enhances the Antitumor Efficacy of Expanded γδT Cells and Overcomes Resistance to Anti–PD-L1 Treatment
Data from IL12/18/21 Preactivation Enhances the Antitumor Efficacy of Expanded γδT Cells and Overcomes Resistance to Anti–PD-L1 Treatment
IL12/18/21 Preactivation Enhances the Antitumor Efficacy of Expanded γδT Cells and Overcomes Resistance to Anti–PD-L1 Treatment
G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma
Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model
Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy
Selective expression of variant surface antigens enables Plasmodium falciparum to evade immune clearance in vivo
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
Induction and Therapeutic Targeting of Human NPM1c+ Myeloid Leukemia in the Presence of Autologous Immune System in Mice
Missing publications? Search for publications with a matching author name.